Medical Products Bill status: drafting, timelines and parliamentary window

1. Key takeaways

In September 2024 the New Zealand Government decided that the Ministry of Health would draft a Medical Products Bill to replace the Medicines Act 1981 (1981 No 118). As of the verification date of 29 October 2026, the bill has not been introduced into Parliament and remains a policy draft: it has no Bill number and no clause text available for verification.

The official progress page is https://www.health.govt.nz/regulation-legislation/medicines-legislation/regulating-medicines-medical-devices-and-natural-health-products. The Ministry’s wording there: “the Ministry is currently developing a new Medical Products Bill to replace the Medicines Act 1981” (another variant reads “is progressing work”; cited per the version captured on the verification date — both point to the same fact: not yet introduced into Parliament).

GRZAN has verified the official sources and confirms two hard facts. First, the official timelines exist in multiple mutually conflicting versions, none officially confirmed. Second, Parliament adjourned on 24 September 2026 and dissolved on 1 October 2026, with the general election on 7 November 2026, so the bill cannot be introduced within the current parliamentary term. Any statement that the bill has passed, or will commence on a definite date, is inconsistent with the official status.

2. Legal basis

The tables below set out each element and the five official timeline versions.

The five official timeline versions (mutually conflicting, none confirmed):

3. Expert insights

Insight 1: five official timelines spanning 2028 to 2030. All five statements come from the Ministry or its officials, yet they are mutually incompatible: commencement is given as 2028, late 2029 and 2030; introduction into Parliament as June 2026, early 2027 and 2027. This is not progressive refinement — the February 2026 version (2030) is later than the November 2024 version (2028), so the timelines are slipping, not converging..

Insight 2: the parliamentary calendar has closed the current window. Parliament adjourned on 24 September 2026, dissolved on 1 October 2026, with the election on 7 November 2026. If a bill is not introduced before dissolution, even a government continuing the same policy must walk the path from drafting to introduction again in a new Parliament. The “June 2026 introduction” version is factually dead — issued in November 2025, while Parliament adjourned in September 2026.

Insight 3: even the bill’s coverage is undetermined. The September 2024 decision is to draft a bill replacing the Medicines Act 1981 — the common parent statute for medicines and medical devices. After the repeal of the TPA 2023, the government confirmed the sector-by-sector route, with natural health products already a standalone bill. Whether and how the bill will cover devices has no official answer as of the verification date. GRZAN’s view: device companies should neither assume the bill will introduce risk-tiered approval for devices nor assume the opposite.

Insight 4: the current regime is unaffected — that much is certain. Whatever happens to the bill, the framework in force is the three-layer structure: the Medicines Act 1981 (current version 10 July 2026), the Medicines Regulations 1984 (SR 1984/143) and the Medicines (Database of Medical Devices) Regulations 2003 (SR 2003/325, current version 7 August 2020). The Sponsor (New Zealand sponsor) must complete WAND notification within 30 working days of becoming a Sponsor and correct inaccurate information within 10 working days, with a fine of up to NZ$500 under reg 14.

Three “gaps in the current regime” should also be recorded: the device side has no GMP licensing and no manufacturing, packing or wholesale licence provisions (the medicines side has the s 17 licensing regime and the s 46(3)(a) GMP evidence duty, and Medsafe’s GMP audit capability covers medicines only); the s 41 mandatory adverse effects reporting duty applies to medicines only, device adverse event reporting being voluntary; and the routine statutory withdrawal tool is reg 50 of the 1984 Regulations, while the s 86 court recall order can issue only where a person has been convicted of s 61 misleading branding — not a general recall tool.

4. Practical recommendations

• Use the standard wording “not yet introduced into Parliament / a policy draft” without exception. GRZAN uses a fixed formulation in all deliverables: as of the verification date (29 October 2026), the Medical Products Bill has not been introduced into Parliament, remains a policy draft, and has no Bill number or clause text; the official timelines exist in multiple versions, none confirmed. Never write it as passed, about to pass, or commencing on a definite date.
• Treat timelines as a range reference, never as a production-planning basis. Consolidate the official statements into the wide range “commencement between 2028 and 2030”, expressly marked as derived from five mutually conflicting versions and not an officially confirmed value (practical estimate). Registration scheduling, inventory planning and contract terms should not rest on a specific year.
• Make “has a Bill number appeared” the only activation signal. Until a Bill number for the Medical Products Bill is found on legislation.govt.nz, all discussion of the bill’s content, coverage and transition arrangements is policy speculation. GRZAN’s monitoring uses this signal as the trigger for clause-level impact assessment.
• Build current obligations on a long-lived assumption. Because the commencement range is wide and uncertain, build standing compliance capability on the current three-layer framework — WAND notification and correction workflows, reg 9 written procedures, the s 38 evidence pack, and the recall and adverse event systems. These capabilities are reusable under any future regime.
• Track policy continuity after the election. The new Parliament’s legislative agenda after the 7 November 2026 election will determine the bill’s actual pace. GRZAN recommends re-checking the Ministry’s progress page and health.govt.nz legislation pages within one month after the election to confirm whether the policy direction continues.

5. Verification checklist

• □ It is confirmed that the Medical Products Bill has not been introduced into Parliament, with no Bill number or clause text
• □ All documents are marked “a policy draft”, never as passed or commencing on a definite date
• □ The September 2024 Cabinet decision (drafting body: Ministry of Health) and the standalone natural health products bill (CAB-26-MIN-0315 / SOU-26-MIN-0085, 25 September 2025) are recorded
• □ The five mutually conflicting official timeline versions (November 2024 / November 2025 / February 2026 / May 2026 / 30 June 2026) are recorded and marked as unconfirmed
• □ Parliament’s adjournment (24 September 2026), dissolution (1 October 2026) and the election (7 November 2026) are recorded
• □ The current three-layer framework and its version dates are recorded (10 July 2026 / 10 July 2026 / 7 August 2020)
• □ The three baseline gaps are confirmed: no device-side GMP / manufacturing licence provisions, s 41 medicines only, s 86 not a general recall tool
• □ The commencement range is handled as the wide 2028–2030 band and marked as a practical estimate
• □ Monitoring is configured with a Bill number as the sole trigger for clause-level assessment

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the New Zealand market. Our team manages adverse event reporting and recall coordination with Medsafe, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com